Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome analysis after glycolysis inhibitors treatment in ocular melanoma cella

ABSTRACT: Transcriptome analysis after glycolysis inhibitors treatment in ocular melanoma cella

PROVIDER: PRJNA658683 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Transcriptome analysis after glycolysis inhibitors treatment in ocular melanoma cella

Project description:In order to study the mechanism of histone lactylation, we used glycolysis inhibitors to reduce histone lactylation and applied RNA-seq and ChIP-seq to identify its target genes in ocular melanoma.

2020-08-23 | GSE156674 | GEO

Transcriptome analysis after treating with LBH589 in ocular melanoma cells

Project description:In order to study the mechanism of histone acetylation affecting development of ocular melanoma, we treated ocular melanoma cells with histone deacetylatase inhibitor LBH589. The results showed that the METTL14 was increased after LBH589 treatment. The study aims to reveal the interaction between histone acetylation and m6A modification, and to further explore the relationship between the expression level of METTL14 and the survival time of ocular melanoma patients, hopefully providing new ideas for the treatment of malignant tumors.

2022-10-02 | GSE214457 | GEO

Transcriptome analysis after METTL14 overexpression in ocular melanoma cells

Project description:In order to study the mechanism of METTL14 and the development of ocular melanoma, we established a model of overexpression of METTL14 in ocular melanoma. The results showed that the expression of FAT4 was increased after METTL14 overexpression. In order to reveal the interaction between METTL14 and FAT4 and to further explore the relationship between the expression level of METTL14 and the survival time of ocular melanoma patients provides new ideas for the treatment of malignant tumors.

2022-10-12 | GSE215095 | GEO

Genome-wide maps of histone lactylation in ocular melanoma by CUT&Tag

Project description:To investigate the function of histone lactylation in ocular melanoma, we analyzed histone lactylation enrichment level in ocular melanoma by CUT&Tag.

2023-09-04 | GSE242018 | GEO

Genome-wide maps of histone lactylation in ocular melanoma by CHIP-seq

Project description:To investigate the function of histone lactylation in ocular melanoma, we analyzed histone lactylation enrichment level in ocular melanoma by CHIP-seq.

2023-09-04 | GSE242013 | GEO

Analysis of N1-methyladenosine methylome (m1A) enrichment level in ocular melanoma.

Project description:To investigate the function of N1-methyladenosine methylome (m1A) in ocular melanoma, we analyzed m1A enrichment level in ocular melanoma and melanocyte cell lines and established ALKBH3 knock down cell lines in 92.1.

2022-09-22 | GSE213748 | GEO

Genome-wide maps of histone lactylation in ocular melanoma

Project description:For the first time, we investigated the role of histone lactylation in tumorgenesis of ocular melanoma.

2020-08-23 | GSE156675 | GEO

Transcriptome analysis after ALKBH3 knockdown in ocular melanoma cells

Project description:To study the mechanism of ALKBH3 in ocular melanoma, we performed RNA-seq of wide type cells and ALKBH3-deficient cells.

2022-09-21 | GSE213681 | GEO

Transcriptome analysis after DOT1L inhibitors treatment in uveal melanoma cells.

Project description:Transcriptome analysis after DOT1L inhibitors treatment in uveal melanoma cells.

| PRJNA750766 | ENA

Combinatorial treatment with PARP and MAPK inhibitors overcomes phenotype switch-driven drug resistance in advanced melanoma

Project description:Metastatic melanoma is either intrinsically resistant or rapidly acquires resistance to targeted therapy treatments, such as MAPK inhibitors. A leading cause of resistance to targeted therapy is a dynamic transition of melanoma cells from a proliferative to a highly invasive state, a phenomenon called phenotype switching. Mechanisms regulating phenotype switching represent potential targets for improving treatment of melanoma patients. Using a drug screen targeting chromatin regulators in patient-derived 3D MAPK inhibitor-resistant melanoma cell cultures, we discovered that PARP inhibitors restore sensitivity to MAPK inhibitors, independent of DNA damage repair pathways. Integrated transcriptomic, proteomic, and epigenomic analyses demonstrated that PARP inhibitors induce lysosomal autophagic cell death, accompanied by enhanced mitochondrial lipid metabolism that ultimately increases antigen presentation and sensitivity to T-cell cytotoxicity. Moreover, transcriptomic and epigenetic rearrangements induced by PARP inhibition reversed EMT-like phenotype switching, which redirected melanoma cells toward a proliferative and MAPK inhibitor-sensitive state. The combination of PARP and MAPK inhibitors synergistically induced cancer cell death both in vitro and in vivo in patient-derived xenograft models. Therefore, this study provides a scientific rationale for treating melanoma patients with PARP inhibitors in combination with MAPK inhibitors to abrogate acquired therapy resistance.

2023-08-24 | GSE221241 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data